Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Altimmune, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its lead product candidate, pemvidutide, during a specified class period [1][2]. Group 1: Allegations - The complaint claims that Altimmune overstated the potential of pemvidutide compared to competing glucagon-like peptide-1 agonists based on the efficacy and tolerability results from the MOMENTUM Trial [1]. - It is alleged that the results of the MOMENTUM Trial were less significant for pemvidutide's clinical, commercial, and competitive prospects than what was communicated to investors [1]. - The lawsuit asserts that the company exaggerated its prospects for finding a strategic partner to develop pemvidutide, leading to materially false and misleading public statements [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as December 1, 2023, to April 26, 2024, and shareholders are encouraged to register for participation [1][2]. - The deadline for shareholders to seek lead plaintiff status is July 5, 2024, and there is no cost or obligation to participate in the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements or omissions that inflate stock prices [3].

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 24, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) investors that a class action has been filed on behalf of investors. Altimmune investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw ...

Core Viewpoint - Altimmune's stock surged approximately 28% following the release of positive results from a 48-week study of its GLP-1 weight-loss drug, pemvidutide, which demonstrated a lower loss of lean mass compared to competing treatments [1][2]. Company Summary - The Phase 2 trial involved 391 participants, with only 21.9% of the weight lost being lean mass, while the remainder was fat loss [2]. - Other GLP-1 drugs have shown that lean mass can account for as much as 40% of total weight loss, highlighting pemvidutide's potential advantage in preserving lean mass [2]. - The CEO of Altimmune emphasized the importance of preserving lean mass for healthy weight loss and physical function [2]. Clinical Results - Participants taking 1.2 mg doses of pemvidutide lost an average of 10.3% of their total weight, while those on 1.8 mg doses lost 11.2%, and those on 2.4 mg doses achieved a mean weight loss of 15.6% [3]. - In contrast, participants receiving placebo doses lost only 2.2% of their weight [3]. Competitive Landscape - Altimmune faces significant competition from established players like Eli Lilly and Novo Nordisk, who are already selling large quantities of GLP-1 drugs [4]. - Additionally, many other companies are developing similar treatments, with 27 new treatments expected to be presented at a recent American Diabetes Association conference [4].

GAITHERSBURG, Md., June 23, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate, in obesity, including the results of a recently completed body composition analysis, at the American Diabetes Association's (ADA) 84th Scientific Sessions. "We're pleased with the data presented at ADA that highlight the impressive lean mass prese ...

GAITHERSBURG, Md., June 23, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate, in obesity, including the results of a recently completed body composition analysis, at the American Diabetes Association’s (ADA) 84th Scientific Sessions. “We’re pleased with the data presented at ADA that highlight the impressive lean mass pres ...

GAITHERSBURG, Md., June 22, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate in development for obesity and metabolic dysfunction-associated steatohepatitis (MASH), on cardioinflammatory lipids at the American Diabetes Association's (ADA) 84th Scientific Sessions. "Dyslipidemia is one of the most significant co-morbidities of obesity, impacting up to 70% of ...

GAITHERSBURG, Md., June 22, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate in development for obesity and metabolic dysfunction-associated steatohepatitis (MASH), on cardioinflammatory lipids at the American Diabetes Association’s (ADA) 84th Scientific Sessions. “Dyslipidemia is one of the most significant co-morbidities of obesity, impacting up to 70% of ...

NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ:ALT) and reminds investors of the July 5, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmu ...

NEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) and reminds investors of the July 5, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimm ...

GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Piper Sandler 2nd Annual Virtual Obesity Investor Day, being held on June 26, 2024, to discuss key takeaways from the American Diabetes Association’s (ADA) Scientific Sessions. Details on the fireside chat are as follows: Title:Piper Sandler Virtual Obesity Investor Day  Present ...